STD Diagnostics Market By Clinical Indications (Human immunodeficiency virus (HIV), Chlamydia, Trichomoniasis, Syphilis, Genital Herpes, Epididymitis, Gonorrhoea, Genital Warts/Human Papillomavirus (HPV), Vaginitis (Atrophic vaginitis, Vulvodynia), Others); By Technologies (Microscopy, Point-of-care (POC) antigen detection tests, Culture, Nucleic acid amplification tests (NAATs), Others); By Test Types (Swab Tests, Urine Tests, Blood Tests, Combinational Tests); By End User(Hospitals, Clinics, Laboratories, Pathological Centres, Research Institutes, Others); By Product Offerings (Test Kits, Reagents, Assays, Probes, Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Sexually transmitted infections (STIs) or sexually transmitted diseases (STDs) are some of the most widespread infections in the world which can occur during sexual or intimate contact with anyone. STDs can also be transmitted by sharing of used needles, during pregnancy and breastfeeding, amongst others. More than 30 different bacteria, viruses and pathogens are transmitted sexually. STDs are becoming a worldwide public health concern as more than 1million STDs are being reported every day. STDs affect both men and women. Individuals younger than 25 years old are highly prone to get these infections due to unprotected and high-risk sexual practices. The statistics of World Health Organization published in June 2019 states that around 376 million new STDs are reported each year. These STDs are having a severe impact on reproductive and sexual health on the global population which can even lead to death in extreme cases. Early detection of STDs can reduce the morbidity rate and help people recover faster without spreading the infection. Technological advancements in medical devices have introduced portable rapid testing solutions for diagnosis of STDs which enable immediate delivery of care to the patients, thus driving the growth of STD diagnostics market. As compared to traditional in-lab testing which requires long time durations for availing the test results, rapid kits produce results in a matter of hours. These portable rapid tests are available for STDs such as Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV), syphilis, amongst others which can be detected by using finger-prick blood or oral fluid. binx health, inc. received clearance from U.S's Food and Drug Administration (FDA) in August 2019 for its portable bench-top platform which diagnose chlamydia and gonorrhoea. Many new market participants such as QuantuMDx Group Ltd., European Union funded SelfDiagnostics and others are developing new portable rapid testing platforms for STDs. Thus, the availability of advanced portable rapid diagnostic devices to curb the growth of STDs amongst individuals is driving the demand for kits in the global STD diagnostics market.
The growing penetration of counterfeit products across the medical supply chain is impacting the growth of the global STD diagnostics market. World Health Organization estimates that up to 8% of the medical devices in circulation are counterfeit. The false diagnosis of these products leads to improper treatment, thus increasing the burden of health costs. These factors have led to stringent regulatory policies and guidelines for production and marketing of STD testing kits. The high regulatory requirements increases time to market of medical devices, thus, hampering the growth of the STD diagnostics market across the globe. Also, the social stigma of STDs is creating hesitance among people for testing which further impedes the growth of market.
Telehealth services for STD diagnosis is rapidly gaining momentum as people are reluctant to discuss their sexual diseases in-person. Online consultation is helping in removing this barrier. The recent outbreak of COVID-19 pandemic has further inflated these telehealth STD diagnostic services as people are restricted to leave their houses amidst lockdowns. To tap on this opportunity, Planned Parenthood Federation of America Inc. announced telehealth services including STD testing across all 50 states in April 2020. In a similar instance, Philadelphia city government is providing telephonic assistance for people with STD amidst COVID-19 crisis. Thus, the recent outbreak of coronavirus pandemic is expected to boost the demand for telehealth services in global STD diagnostics market in future years.
Clinical Indications Outlook:
Syphilis is a rapidly emerging STD which is drawing attention of various healthcare entities. As per World Health Organization’s estimates, in 2016, there were approximately 6 million new cases of syphilis worldwide. When Syphilis is allowed to proceed to its tertiary stage, it can lead to severe neurological problems. The Syphilis infection is more concerning because it can cross the placenta of pregnant women and infect the babies in the womb. The U.S Centers for Disease Control and Prevention stated that congenital syphilis caused the death of 94 new born babies in 2018, which was 22% higher from previous year. This trend has made early prenatal care and STD testing essential amongst pregnant women to safeguard mothers and their babies from of Syphilis. People detected with syphilis are also at a greater risk of getting HIV which makes diagnosis and treatment of the disease highly important. To tackle this spread of STDs, World Health Organization in partnership with the Chinese government launched 'Eliminating HIV/AIDS mother-to-child transmission: China is in action’ initiative in 2017 to eliminate mother-to-child transmission of Syphilis and other STDs. Thus, the increasing occurrence of Syphilis and its transfer from the mother to child is propelling its share in global STD diagnostics market.
End User Outlook:
Multiple research and surveys show that many patients and some doctors are reluctant to discuss STD screening and disease risks. To tackle this challenge, point of care test kits are being introduced for individuals to perform STD diagnosis at home and consult the doctor only if tested positive. For instance, Quest Diagnostics Inc. launched STD diagnostics kit in April 2019 for testing HIV, Hepatitis B and C, Syphilis, Gonorrhea, Chlamydia and Trichomonas at home at a cost of US$ 49 for an individual test. These new tests are anticipated to gain momentum in global STD diagnostics market in future years.
Regional Outlook:
North America region registered the highest share in global STD diagnostics market in 2018. According to the Sexually Transmitted Disease Surveillance Report released by the Centers for Disease Control and Prevention of the U.S in 2018, the combined number of Chlamydia, Gonorrhea and Syphilis across the nation reached a record of 2.457 million cases in 2018. U.S. Department of Health and Human Services states that there are approximately 20 million new cases of STDs each year which bears a cost of US$ 16 billion on the nation’s health care system. These growing number of detected and reported cases of STDs are contributing towards high share of North America in the global STD diagnostics market.
Asia Pacific region is anticipated to gain momentum over the forecast period owing to government initiatives to curb the rise in number of STDs. Low and middle income nations of this region are witnessing an upsurge in the number of STDs due to social beliefs, poverty, unstable housing and other factors, which reduces the access to STD prevention and care materials. Also, the lack of awareness regarding STDs is a major factor boosting its prevalence across these nations. For instance, China accounts for 3% of new HIV infections around the globe. To tackle this rise, it has increased its HIV testing facilities from 7,600 to 30,500 in 2017 which performed 201 million tests annually. The nation also launched its National Programme for Prevention and Control of Syphilis (2010?2020). These initiatives by are anticipated to drive the share of Asia Pacific region in the global STD diagnostics market.
In terms of revenue, global STD diagnostics market was valued at US$ 88706.7 Mn in 2018 and is anticipated to grow at a CAGR of 5.06% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global STD Diagnostics Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of STD diagnostics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the STD diagnostics market are Abbott Laboratories, BD, bioMérieux SA, Bio-Rad Laboratories, Inc., Cellabs, Cepheid, Danaher Corporation, DiaSorinS.p.A., EUROSPITAL SPA, F. Hoffmann-La Roche Ltd, Hologic, Inc., JAL Medical (OK Biotech Co. Ltd.), MedMira Inc., OraSure Technologies, Inc., QIAGEN, Quest Diagnostics, Quidel Corporation, Rapikit.com and Siemens Healthcare GmbH amongst others.
Global STD Diagnostics Market:
By Clinical Indications
- Human immunodeficiency virus (HIV)
- Chlamydia
- Trichomoniasis
- Syphilis
- Genital Herpes
- Epididymitis
- Gonorrhoea
- Genital Warts/Human Papillomavirus (HPV)
- Vaginitis
- Atrophic vaginitis
- Vulvodynia
- Others
By Technologies
- Microscopy
- Point-of-care (POC) antigen detection tests
- Culture
- Nucleic acid amplification tests (NAATs)
- Others
By Test Types
- Swab Tests
- Urine Tests
- Blood Tests
- Combinational Tests
By End User
- Hospitals
- Clinics
- Laboratories
- Pathological Centres
- Research Institutes
- Others
By Product Offerings
- Test Kits
- Reagents
- Assays
- Probes
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of STD Diagnostics Market
6. Market
Synopsis: STD Diagnostics Market
7. STD
Diagnostics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
STD Diagnostics Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: STD Diagnostics Market
7.6. Analysis
of COVID-19 Impact on STD Diagnostics Market
8. Global STD
Diagnostics Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
STD Diagnostics Market Revenue (US$ Mn)
8.2. Global STD
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
8.2.1. Human
immunodeficiency virus (HIV)
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Chlamydia
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Trichomoniasis
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Syphilis
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2013 – 2018
8.2.4.3. Market
Forecast, 2019 – 2027
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2013 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2013 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2013 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2013 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2013 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.2.5. Genital
Herpes
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2013 – 2018
8.2.5.3. Market
Forecast, 2019 – 2027
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2013 – 2018
8.2.5.5.1.2. Market
Forecast, 2019 – 2027
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2013 – 2018
8.2.5.5.2.2. Market
Forecast, 2019 – 2027
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2013 – 2018
8.2.5.5.3.2. Market
Forecast, 2019 – 2027
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2013 – 2018
8.2.5.5.4.2. Market
Forecast, 2019 – 2027
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2013 – 2018
8.2.5.5.5.2. Market
Forecast, 2019 – 2027
8.2.6. Epididymitis
8.2.6.1. Definition
8.2.6.2. Market
Estimation and Penetration, 2013 – 2018
8.2.6.3. Market
Forecast, 2019 – 2027
8.2.6.4. Compound
Annual Growth Rate (CAGR)
8.2.6.5. Regional
Bifurcation
8.2.6.5.1. North
America
8.2.6.5.1.1. Market
Estimation, 2013 – 2018
8.2.6.5.1.2. Market
Forecast, 2019 – 2027
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2013 – 2018
8.2.6.5.2.2. Market
Forecast, 2019 – 2027
8.2.6.5.3. Asia
Pacific
8.2.6.5.3.1. Market
Estimation, 2013 – 2018
8.2.6.5.3.2. Market
Forecast, 2019 – 2027
8.2.6.5.4. Middle
East and Africa
8.2.6.5.4.1. Market
Estimation, 2013 – 2018
8.2.6.5.4.2. Market
Forecast, 2019 – 2027
8.2.6.5.5. Latin
America
8.2.6.5.5.1. Market
Estimation, 2013 – 2018
8.2.6.5.5.2. Market
Forecast, 2019 – 2027
8.2.7. Gonorrhoea
8.2.7.1. Definition
8.2.7.2. Market
Estimation and Penetration, 2013 – 2018
8.2.7.3. Market
Forecast, 2019 – 2027
8.2.7.4. Compound
Annual Growth Rate (CAGR)
8.2.7.5. Regional
Bifurcation
8.2.7.5.1. North
America
8.2.7.5.1.1. Market
Estimation, 2013 – 2018
8.2.7.5.1.2. Market
Forecast, 2019 – 2027
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2013 – 2018
8.2.7.5.2.2. Market
Forecast, 2019 – 2027
8.2.7.5.3. Asia
Pacific
8.2.7.5.3.1. Market
Estimation, 2013 – 2018
8.2.7.5.3.2. Market
Forecast, 2019 – 2027
8.2.7.5.4. Middle
East and Africa
8.2.7.5.4.1. Market
Estimation, 2013 – 2018
8.2.7.5.4.2. Market
Forecast, 2019 – 2027
8.2.7.5.5. Latin
America
8.2.7.5.5.1. Market
Estimation, 2013 – 2018
8.2.7.5.5.2. Market
Forecast, 2019 – 2027
8.2.8. Genital
Warts/Human Papillomavirus (HPV)
8.2.8.1. Definition
8.2.8.2. Market
Estimation and Penetration, 2013 – 2018
8.2.8.3. Market
Forecast, 2019 – 2027
8.2.8.4. Compound
Annual Growth Rate (CAGR)
8.2.8.5. Regional
Bifurcation
8.2.8.5.1. North
America
8.2.8.5.1.1. Market
Estimation, 2013 – 2018
8.2.8.5.1.2. Market
Forecast, 2019 – 2027
8.2.8.5.2. Europe
8.2.8.5.2.1. Market
Estimation, 2013 – 2018
8.2.8.5.2.2. Market
Forecast, 2019 – 2027
8.2.8.5.3. Asia
Pacific
8.2.8.5.3.1. Market
Estimation, 2013 – 2018
8.2.8.5.3.2. Market
Forecast, 2019 – 2027
8.2.8.5.4. Middle
East and Africa
8.2.8.5.4.1. Market
Estimation, 2013 – 2018
8.2.8.5.4.2. Market
Forecast, 2019 – 2027
8.2.8.5.5. Latin
America
8.2.8.5.5.1. Market
Estimation, 2013 – 2018
8.2.8.5.5.2. Market
Forecast, 2019 – 2027
8.2.9. Vaginitis
(Definition, Market Estimation and Penetration, 2013 – 2018, Market Estimation
(2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Atrophic vaginitis, Vulvodynia)
8.2.9.1. Atrophic
vaginitis
8.2.9.2. Vulvodynia
8.2.10. Others
8.2.10.1. Definition
8.2.10.2. Market
Estimation and Penetration, 2013 – 2018
8.2.10.3. Market
Forecast, 2019 – 2027
8.2.10.4. Compound
Annual Growth Rate (CAGR)
8.2.10.5. Regional
Bifurcation
8.2.10.5.1. North
America
8.2.10.5.1.1. Market
Estimation, 2013 – 2018
8.2.10.5.1.2. Market
Forecast, 2019 – 2027
8.2.10.5.2. Europe
8.2.10.5.2.1. Market
Estimation, 2013 – 2018
8.2.10.5.2.2. Market
Forecast, 2019 – 2027
8.2.10.5.3. Asia
Pacific
8.2.10.5.3.1. Market
Estimation, 2013 – 2018
8.2.10.5.3.2. Market
Forecast, 2019 – 2027
8.2.10.5.4. Middle
East and Africa
8.2.10.5.4.1. Market
Estimation, 2013 – 2018
8.2.10.5.4.2. Market
Forecast, 2019 – 2027
8.2.10.5.5. Latin
America
8.2.10.5.5.1. Market
Estimation, 2013 – 2018
8.2.10.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Clinical Indications
9. Global STD
Diagnostics Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global STD
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
9.2.1. Microscopy
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Point-of-care
(POC) antigen detection tests
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Culture
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Nucleic
acid amplification tests (NAATs)
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2013 – 2018
9.2.5.3. Market
Forecast, 2019 – 2027
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2013 – 2018
9.2.5.5.1.2. Market
Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2018
9.2.5.5.2.2. Market
Forecast, 2019 – 2027
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2018
9.2.5.5.3.2. Market
Forecast, 2019 – 2027
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2018
9.2.5.5.4.2. Market
Forecast, 2019 – 2027
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2013 – 2018
9.2.5.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Technologies
10. Global STD
Diagnostics Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
10.2.1. Swab
Tests
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Urine
Tests
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Blood
Tests
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.2.4. Combinational
Tests
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2013 – 2018
10.2.4.3. Market
Forecast, 2019 – 2027
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2013 – 2018
10.2.4.5.1.2. Market
Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2013 – 2018
10.2.4.5.2.2. Market
Forecast, 2019 – 2027
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2013 – 2018
10.2.4.5.3.2. Market
Forecast, 2019 – 2027
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2013 – 2018
10.2.4.5.4.2. Market
Forecast, 2019 – 2027
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2013 – 2018
10.2.4.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By Test
Types
11. Global STD
Diagnostics Market Analysis and Forecasts, 2019 – 2027
11.1. Overview
11.2. Global
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
11.2.1. Hospitals
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2013 – 2018
11.2.1.3. Market
Forecast, 2019 – 2027
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2013 – 2018
11.2.1.5.1.2. Market
Forecast, 2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2013 – 2018
11.2.1.5.2.2. Market
Forecast, 2019 – 2027
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2013 – 2018
11.2.1.5.3.2. Market
Forecast, 2019 – 2027
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2013 – 2018
11.2.1.5.4.2. Market
Forecast, 2019 – 2027
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2013 – 2018
11.2.1.5.5.2. Market
Forecast, 2019 – 2027
11.2.2. Clinics
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2013 – 2018
11.2.2.3. Market
Forecast, 2019 – 2027
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2013 – 2018
11.2.2.5.1.2. Market
Forecast, 2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2013 – 2018
11.2.2.5.2.2. Market
Forecast, 2019 – 2027
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2013 – 2018
11.2.2.5.3.2. Market
Forecast, 2019 – 2027
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2013 – 2018
11.2.2.5.4.2. Market
Forecast, 2019 – 2027
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2013 – 2018
11.2.2.5.5.2. Market
Forecast, 2019 – 2027
11.2.3. Laboratories
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2013 – 2018
11.2.3.3. Market
Forecast, 2019 – 2027
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2013 – 2018
11.2.3.5.1.2. Market
Forecast, 2019 – 2027
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2013 – 2018
11.2.3.5.2.2. Market
Forecast, 2019 – 2027
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2013 – 2018
11.2.3.5.3.2. Market
Forecast, 2019 – 2027
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2013 – 2018
11.2.3.5.4.2. Market
Forecast, 2019 – 2027
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2013 – 2018
11.2.3.5.5.2. Market
Forecast, 2019 – 2027
11.2.4. Pathological
Centres
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2013 – 2018
11.2.4.3. Market
Forecast, 2019 – 2027
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2013 – 2018
11.2.4.5.1.2. Market
Forecast, 2019 – 2027
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2013 – 2018
11.2.4.5.2.2. Market
Forecast, 2019 – 2027
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2013 – 2018
11.2.4.5.3.2. Market
Forecast, 2019 – 2027
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2013 – 2018
11.2.4.5.4.2. Market
Forecast, 2019 – 2027
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2013 – 2018
11.2.4.5.5.2. Market
Forecast, 2019 – 2027
11.2.5. Research
Institutes
11.2.5.1. Definition
11.2.5.2. Market
Estimation and Penetration, 2013 – 2018
11.2.5.3. Market
Forecast, 2019 – 2027
11.2.5.4. Compound
Annual Growth Rate (CAGR)
11.2.5.5. Regional
Bifurcation
11.2.5.5.1. North
America
11.2.5.5.1.1. Market
Estimation, 2013 – 2018
11.2.5.5.1.2. Market
Forecast, 2019 – 2027
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2013 – 2018
11.2.5.5.2.2. Market
Forecast, 2019 – 2027
11.2.5.5.3. Asia
Pacific
11.2.5.5.3.1. Market
Estimation, 2013 – 2018
11.2.5.5.3.2. Market
Forecast, 2019 – 2027
11.2.5.5.4. Middle
East and Africa
11.2.5.5.4.1. Market
Estimation, 2013 – 2018
11.2.5.5.4.2. Market
Forecast, 2019 – 2027
11.2.5.5.5. Latin
America
11.2.5.5.5.1. Market
Estimation, 2013 – 2018
11.2.5.5.5.2. Market
Forecast, 2019 – 2027
11.2.6. Others
11.2.6.1. Definition
11.2.6.2. Market
Estimation and Penetration, 2013 – 2018
11.2.6.3. Market
Forecast, 2019 – 2027
11.2.6.4. Compound
Annual Growth Rate (CAGR)
11.2.6.5. Regional
Bifurcation
11.2.6.5.1. North
America
11.2.6.5.1.1. Market
Estimation, 2013 – 2018
11.2.6.5.1.2. Market
Forecast, 2019 – 2027
11.2.6.5.2. Europe
11.2.6.5.2.1. Market
Estimation, 2013 – 2018
11.2.6.5.2.2. Market
Forecast, 2019 – 2027
11.2.6.5.3. Asia
Pacific
11.2.6.5.3.1. Market
Estimation, 2013 – 2018
11.2.6.5.3.2. Market
Forecast, 2019 – 2027
11.2.6.5.4. Middle
East and Africa
11.2.6.5.4.1. Market
Estimation, 2013 – 2018
11.2.6.5.4.2. Market
Forecast, 2019 – 2027
11.2.6.5.5. Latin
America
11.2.6.5.5.1. Market
Estimation, 2013 – 2018
11.2.6.5.5.2. Market
Forecast, 2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By End
User
12. Global STD
Diagnostics Market Analysis and Forecasts, 2019 – 2027
12.1. Overview
12.2. Global
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
12.2.1. Test
Kits
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2013 – 2018
12.2.1.3. Market
Forecast, 2019 – 2027
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2013 – 2018
12.2.1.5.1.2. Market
Forecast, 2019 – 2027
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2013 – 2018
12.2.1.5.2.2. Market
Forecast, 2019 – 2027
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2013 – 2018
12.2.1.5.3.2. Market
Forecast, 2019 – 2027
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2013 – 2018
12.2.1.5.4.2. Market
Forecast, 2019 – 2027
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2013 – 2018
12.2.1.5.5.2. Market
Forecast, 2019 – 2027
12.2.2. Reagents
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2013 – 2018
12.2.2.3. Market
Forecast, 2019 – 2027
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2013 – 2018
12.2.2.5.1.2. Market
Forecast, 2019 – 2027
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2013 – 2018
12.2.2.5.2.2. Market
Forecast, 2019 – 2027
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2013 – 2018
12.2.2.5.3.2. Market
Forecast, 2019 – 2027
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2013 – 2018
12.2.2.5.4.2. Market
Forecast, 2019 – 2027
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2013 – 2018
12.2.2.5.5.2. Market
Forecast, 2019 – 2027
12.2.3. Assays
12.2.3.1. Definition
12.2.3.2. Market
Estimation and Penetration, 2013 – 2018
12.2.3.3. Market
Forecast, 2019 – 2027
12.2.3.4. Compound
Annual Growth Rate (CAGR)
12.2.3.5. Regional
Bifurcation
12.2.3.5.1. North
America
12.2.3.5.1.1. Market
Estimation, 2013 – 2018
12.2.3.5.1.2. Market
Forecast, 2019 – 2027
12.2.3.5.2. Europe
12.2.3.5.2.1. Market
Estimation, 2013 – 2018
12.2.3.5.2.2. Market
Forecast, 2019 – 2027
12.2.3.5.3. Asia
Pacific
12.2.3.5.3.1. Market
Estimation, 2013 – 2018
12.2.3.5.3.2. Market
Forecast, 2019 – 2027
12.2.3.5.4. Middle
East and Africa
12.2.3.5.4.1. Market
Estimation, 2013 – 2018
12.2.3.5.4.2. Market
Forecast, 2019 – 2027
12.2.3.5.5. Latin
America
12.2.3.5.5.1. Market
Estimation, 2013 – 2018
12.2.3.5.5.2. Market
Forecast, 2019 – 2027
12.2.4. Probes
12.2.4.1. Definition
12.2.4.2. Market
Estimation and Penetration, 2013 – 2018
12.2.4.3. Market
Forecast, 2019 – 2027
12.2.4.4. Compound
Annual Growth Rate (CAGR)
12.2.4.5. Regional
Bifurcation
12.2.4.5.1. North
America
12.2.4.5.1.1. Market
Estimation, 2013 – 2018
12.2.4.5.1.2. Market
Forecast, 2019 – 2027
12.2.4.5.2. Europe
12.2.4.5.2.1. Market
Estimation, 2013 – 2018
12.2.4.5.2.2. Market
Forecast, 2019 – 2027
12.2.4.5.3. Asia
Pacific
12.2.4.5.3.1. Market
Estimation, 2013 – 2018
12.2.4.5.3.2. Market
Forecast, 2019 – 2027
12.2.4.5.4. Middle
East and Africa
12.2.4.5.4.1. Market
Estimation, 2013 – 2018
12.2.4.5.4.2. Market
Forecast, 2019 – 2027
12.2.4.5.5. Latin
America
12.2.4.5.5.1. Market
Estimation, 2013 – 2018
12.2.4.5.5.2. Market
Forecast, 2019 – 2027
12.2.5. Others
12.2.5.1. Definition
12.2.5.2. Market
Estimation and Penetration, 2013 – 2018
12.2.5.3. Market
Forecast, 2019 – 2027
12.2.5.4. Compound
Annual Growth Rate (CAGR)
12.2.5.5. Regional
Bifurcation
12.2.5.5.1. North
America
12.2.5.5.1.1. Market
Estimation, 2013 – 2018
12.2.5.5.1.2. Market
Forecast, 2019 – 2027
12.2.5.5.2. Europe
12.2.5.5.2.1. Market
Estimation, 2013 – 2018
12.2.5.5.2.2. Market
Forecast, 2019 – 2027
12.2.5.5.3. Asia
Pacific
12.2.5.5.3.1. Market
Estimation, 2013 – 2018
12.2.5.5.3.2. Market
Forecast, 2019 – 2027
12.2.5.5.4. Middle
East and Africa
12.2.5.5.4.1. Market
Estimation, 2013 – 2018
12.2.5.5.4.2. Market
Forecast, 2019 – 2027
12.2.5.5.5. Latin
America
12.2.5.5.5.1. Market
Estimation, 2013 – 2018
12.2.5.5.5.2. Market
Forecast, 2019 – 2027
12.3. Key
Segment for Channeling Investments
12.3.1. By
Product Offerings
13. North
America STD Diagnostics Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. North
America STD Diagnostics Market Revenue (US$ Mn)
13.2. North
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
13.2.1. Human
immunodeficiency virus (HIV)
13.2.2. Chlamydia
13.2.3. Trichomoniasis
13.2.4. Syphilis
13.2.5. Genital
Herpes
13.2.6. Epididymitis
13.2.7. Gonorrhoea
13.2.8. Genital
Warts/Human Papillomavirus (HPV)
13.2.9. Vaginitis
13.2.9.1. Atrophic
vaginitis
13.2.9.2. Vulvodynia
13.2.10. Others
13.3. North
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
13.3.1. Microscopy
13.3.2. Point-of-care
(POC) antigen detection tests
13.3.3. Culture
13.3.4. Nucleic
acid amplification tests (NAATs)
13.3.5. Others
13.4. North
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
13.4.1. Swab
Tests
13.4.2. Urine
Tests
13.4.3. Blood
Tests
13.4.4. Combinational
Tests
13.5. North
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Laboratories
13.5.4. Pathological
Centres
13.5.5. Research
Institutes
13.5.6. Others
13.6. North
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
13.6.1. Test
Kits
13.6.2. Reagents
13.6.3. Assays
13.6.4. Probes
13.6.5. Others
13.7. North
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
13.7.1.1.1. Human
immunodeficiency virus (HIV)
13.7.1.1.2. Chlamydia
13.7.1.1.3. Trichomoniasis
13.7.1.1.4. Syphilis
13.7.1.1.5. Genital
Herpes
13.7.1.1.6. Epididymitis
13.7.1.1.7. Gonorrhoea
13.7.1.1.8. Genital
Warts/Human Papillomavirus (HPV)
13.7.1.1.9. Vaginitis
13.7.1.1.9.1. Atrophic
vaginitis
13.7.1.1.9.2. Vulvodynia
13.7.1.1.10. Others
13.7.1.2. U.S
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
13.7.1.2.1. Microscopy
13.7.1.2.2. Point-of-care
(POC) antigen detection tests
13.7.1.2.3. Culture
13.7.1.2.4. Nucleic
acid amplification tests (NAATs)
13.7.1.2.5. Others
13.7.1.3. U.S
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
13.7.1.3.1. Swab
Tests
13.7.1.3.2. Urine
Tests
13.7.1.3.3. Blood
Tests
13.7.1.3.4. Combinational
Tests
13.7.1.4. U.S
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.7.1.4.1. Hospitals
13.7.1.4.2. Clinics
13.7.1.4.3. Laboratories
13.7.1.4.4. Pathological
Centres
13.7.1.4.5. Research
Institutes
13.7.1.4.6. Others
13.7.1.5. U.S
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
13.7.1.5.1. Test
Kits
13.7.1.5.2. Reagents
13.7.1.5.3. Assays
13.7.1.5.4. Probes
13.7.1.5.5. Others
13.7.2. Canada
13.7.2.1. Canada
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
13.7.2.1.1. Human
immunodeficiency virus (HIV)
13.7.2.1.2. Chlamydia
13.7.2.1.3. Trichomoniasis
13.7.2.1.4. Syphilis
13.7.2.1.5. Genital
Herpes
13.7.2.1.6. Epididymitis
13.7.2.1.7. Gonorrhoea
13.7.2.1.8. Genital
Warts/Human Papillomavirus (HPV)
13.7.2.1.9. Vaginitis
13.7.2.1.9.1. Atrophic
vaginitis
13.7.2.1.9.2. Vulvodynia
13.7.2.1.10. Others
13.7.2.2. Canada
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
13.7.2.2.1. Microscopy
13.7.2.2.2. Point-of-care
(POC) antigen detection tests
13.7.2.2.3. Culture
13.7.2.2.4. Nucleic
acid amplification tests (NAATs)
13.7.2.2.5. Others
13.7.2.3. Canada
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
13.7.2.3.1. Swab
Tests
13.7.2.3.2. Urine
Tests
13.7.2.3.3. Blood
Tests
13.7.2.3.4. Combinational
Tests
13.7.2.4. Canada
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.7.2.4.1. Hospitals
13.7.2.4.2. Clinics
13.7.2.4.3. Laboratories
13.7.2.4.4. Pathological
Centres
13.7.2.4.5. Research
Institutes
13.7.2.4.6. Others
13.7.2.5. Canada
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
13.7.2.5.1. Test
Kits
13.7.2.5.2. Reagents
13.7.2.5.3. Assays
13.7.2.5.4. Probes
13.7.2.5.5. Others
13.7.3. Mexico
13.7.3.1. Mexico
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
13.7.3.1.1. Human
immunodeficiency virus (HIV)
13.7.3.1.2. Chlamydia
13.7.3.1.3. Trichomoniasis
13.7.3.1.4. Syphilis
13.7.3.1.5. Genital
Herpes
13.7.3.1.6. Epididymitis
13.7.3.1.7. Gonorrhoea
13.7.3.1.8. Genital
Warts/Human Papillomavirus (HPV)
13.7.3.1.9. Vaginitis
13.7.3.1.9.1. Atrophic
vaginitis
13.7.3.1.9.2. Vulvodynia
13.7.3.1.10. Others
13.7.3.2. Mexico
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
13.7.3.2.1. Microscopy
13.7.3.2.2. Point-of-care
(POC) antigen detection tests
13.7.3.2.3. Culture
13.7.3.2.4. Nucleic
acid amplification tests (NAATs)
13.7.3.2.5. Others
13.7.3.3. Mexico
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
13.7.3.3.1. Swab
Tests
13.7.3.3.2. Urine
Tests
13.7.3.3.3. Blood
Tests
13.7.3.3.4. Combinational
Tests
13.7.3.4. Mexico
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.7.3.4.1. Hospitals
13.7.3.4.2. Clinics
13.7.3.4.3. Laboratories
13.7.3.4.4. Pathological
Centres
13.7.3.4.5. Research
Institutes
13.7.3.4.6. Others
13.7.3.5. Mexico
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
13.7.3.5.1. Test
Kits
13.7.3.5.2. Reagents
13.7.3.5.3. Assays
13.7.3.5.4. Probes
13.7.3.5.5. Others
13.7.4. Rest of
North America
13.7.4.1. Rest
of North America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Clinical Indications
13.7.4.1.1. Human
immunodeficiency virus (HIV)
13.7.4.1.2. Chlamydia
13.7.4.1.3. Trichomoniasis
13.7.4.1.4. Syphilis
13.7.4.1.5. Genital
Herpes
13.7.4.1.6. Epididymitis
13.7.4.1.7. Gonorrhoea
13.7.4.1.8. Genital
Warts/Human Papillomavirus (HPV)
13.7.4.1.9. Vaginitis
13.7.4.1.9.1. Atrophic
vaginitis
13.7.4.1.9.2. Vulvodynia
13.7.4.1.10. Others
13.7.4.2. Rest
of North America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technologies
13.7.4.2.1. Microscopy
13.7.4.2.2. Point-of-care
(POC) antigen detection tests
13.7.4.2.3. Culture
13.7.4.2.4. Nucleic
acid amplification tests (NAATs)
13.7.4.2.5. Others
13.7.4.3. Rest
of North America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test
Types
13.7.4.3.1. Swab
Tests
13.7.4.3.2. Urine
Tests
13.7.4.3.3. Blood
Tests
13.7.4.3.4. Combinational
Tests
13.7.4.4. Rest
of North America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End
User
13.7.4.4.1. Hospitals
13.7.4.4.2. Clinics
13.7.4.4.3. Laboratories
13.7.4.4.4. Pathological
Centres
13.7.4.4.5. Research
Institutes
13.7.4.4.6. Others
13.7.4.5. Rest
of North America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Product Offerings
13.7.4.5.1. Test
Kits
13.7.4.5.2. Reagents
13.7.4.5.3. Assays
13.7.4.5.4. Probes
13.7.4.5.5. Others
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By
Clinical Indications
13.8.3. By
Technologies
13.8.4. By Test
Types
13.8.5. By End
User
13.8.6. By
Product Offerings
14. Europe STD
Diagnostics Market Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Europe
STD Diagnostics Market Revenue (US$ Mn)
14.2. Europe
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
14.2.1. Human
immunodeficiency virus (HIV)
14.2.2. Chlamydia
14.2.3. Trichomoniasis
14.2.4. Syphilis
14.2.5. Genital
Herpes
14.2.6. Epididymitis
14.2.7. Gonorrhoea
14.2.8. Genital
Warts/Human Papillomavirus (HPV)
14.2.9. Vaginitis
14.2.9.1. Atrophic
vaginitis
14.2.9.2. Vulvodynia
14.2.10. Others
14.3. Europe
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
14.3.1. Microscopy
14.3.2. Point-of-care
(POC) antigen detection tests
14.3.3. Culture
14.3.4. Nucleic
acid amplification tests (NAATs)
14.3.5. Others
14.4. Europe
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.4.1. Swab
Tests
14.4.2. Urine
Tests
14.4.3. Blood
Tests
14.4.4. Combinational
Tests
14.5. Europe
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Laboratories
14.5.4. Pathological
Centres
14.5.5. Research
Institutes
14.5.6. Others
14.6. Europe
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
14.6.1. Test
Kits
14.6.2. Reagents
14.6.3. Assays
14.6.4. Probes
14.6.5. Others
14.7. Europe
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1. France
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
14.7.1.1.1. Human
immunodeficiency virus (HIV)
14.7.1.1.2. Chlamydia
14.7.1.1.3. Trichomoniasis
14.7.1.1.4. Syphilis
14.7.1.1.5. Genital
Herpes
14.7.1.1.6. Epididymitis
14.7.1.1.7. Gonorrhoea
14.7.1.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.1.1.9. Vaginitis
14.7.1.1.9.1. Atrophic
vaginitis
14.7.1.1.9.2. Vulvodynia
14.7.1.1.10. Others
14.7.1.2. France
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
14.7.1.2.1. Microscopy
14.7.1.2.2. Point-of-care
(POC) antigen detection tests
14.7.1.2.3. Culture
14.7.1.2.4. Nucleic
acid amplification tests (NAATs)
14.7.1.2.5. Others
14.7.1.3. France
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.1.3.1. Swab
Tests
14.7.1.3.2. Urine
Tests
14.7.1.3.3. Blood
Tests
14.7.1.3.4. Combinational
Tests
14.7.1.4. France
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.1.4.1. Hospitals
14.7.1.4.2. Clinics
14.7.1.4.3. Laboratories
14.7.1.4.4. Pathological
Centres
14.7.1.4.5. Research
Institutes
14.7.1.4.6. Others
14.7.1.5. France
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
14.7.1.5.1. Test
Kits
14.7.1.5.2. Reagents
14.7.1.5.3. Assays
14.7.1.5.4. Probes
14.7.1.5.5. Others
14.7.2. The UK
14.7.2.1. The
UK STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
14.7.2.1.1. Human
immunodeficiency virus (HIV)
14.7.2.1.2. Chlamydia
14.7.2.1.3. Trichomoniasis
14.7.2.1.4. Syphilis
14.7.2.1.5. Genital
Herpes
14.7.2.1.6. Epididymitis
14.7.2.1.7. Gonorrhoea
14.7.2.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.2.1.9. Vaginitis
14.7.2.1.9.1. Atrophic
vaginitis
14.7.2.1.9.2. Vulvodynia
14.7.2.1.10. Others
14.7.2.2. The
UK STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
14.7.2.2.1. Microscopy
14.7.2.2.2. Point-of-care
(POC) antigen detection tests
14.7.2.2.3. Culture
14.7.2.2.4. Nucleic
acid amplification tests (NAATs)
14.7.2.2.5. Others
14.7.2.3. The
UK STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.2.3.1. Swab
Tests
14.7.2.3.2. Urine
Tests
14.7.2.3.3. Blood
Tests
14.7.2.3.4. Combinational
Tests
14.7.2.4. The
UK STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.2.4.1. Hospitals
14.7.2.4.2. Clinics
14.7.2.4.3. Laboratories
14.7.2.4.4. Pathological
Centres
14.7.2.4.5. Research
Institutes
14.7.2.4.6. Others
14.7.2.5. The
UK STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
14.7.2.5.1. Test
Kits
14.7.2.5.2. Reagents
14.7.2.5.3. Assays
14.7.2.5.4. Probes
14.7.2.5.5. Others
14.7.3. Spain
14.7.3.1. Spain
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
14.7.3.1.1. Human
immunodeficiency virus (HIV)
14.7.3.1.2. Chlamydia
14.7.3.1.3. Trichomoniasis
14.7.3.1.4. Syphilis
14.7.3.1.5. Genital
Herpes
14.7.3.1.6. Epididymitis
14.7.3.1.7. Gonorrhoea
14.7.3.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.3.1.9. Vaginitis
14.7.3.1.9.1. Atrophic
vaginitis
14.7.3.1.9.2. Vulvodynia
14.7.3.1.10. Others
14.7.3.2. Spain
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
14.7.3.2.1. Microscopy
14.7.3.2.2. Point-of-care
(POC) antigen detection tests
14.7.3.2.3. Culture
14.7.3.2.4. Nucleic
acid amplification tests (NAATs)
14.7.3.2.5. Others
14.7.3.3. Spain
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.3.3.1. Swab
Tests
14.7.3.3.2. Urine
Tests
14.7.3.3.3. Blood
Tests
14.7.3.3.4. Combinational
Tests
14.7.3.4. Spain
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.3.4.1. Hospitals
14.7.3.4.2. Clinics
14.7.3.4.3. Laboratories
14.7.3.4.4. Pathological
Centres
14.7.3.4.5. Research
Institutes
14.7.3.4.6. Others
14.7.3.5. Spain
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
14.7.3.5.1. Test
Kits
14.7.3.5.2. Reagents
14.7.3.5.3. Assays
14.7.3.5.4. Probes
14.7.3.5.5. Others
14.7.4. Germany
14.7.4.1. Germany
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
14.7.4.1.1. Human
immunodeficiency virus (HIV)
14.7.4.1.2. Chlamydia
14.7.4.1.3. Trichomoniasis
14.7.4.1.4. Syphilis
14.7.4.1.5. Genital
Herpes
14.7.4.1.6. Epididymitis
14.7.4.1.7. Gonorrhoea
14.7.4.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.4.1.9. Vaginitis
14.7.4.1.9.1. Atrophic
vaginitis
14.7.4.1.9.2. Vulvodynia
14.7.4.1.10. Others
14.7.4.2. Germany
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
14.7.4.2.1. Microscopy
14.7.4.2.2. Point-of-care
(POC) antigen detection tests
14.7.4.2.3. Culture
14.7.4.2.4. Nucleic
acid amplification tests (NAATs)
14.7.4.2.5. Others
14.7.4.3. Germany
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.4.3.1. Swab
Tests
14.7.4.3.2. Urine
Tests
14.7.4.3.3. Blood
Tests
14.7.4.3.4. Combinational
Tests
14.7.4.4. Germany
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.4.4.1. Hospitals
14.7.4.4.2. Clinics
14.7.4.4.3. Laboratories
14.7.4.4.4. Pathological
Centres
14.7.4.4.5. Research
Institutes
14.7.4.4.6. Others
14.7.4.5. Germany
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
14.7.4.5.1. Test
Kits
14.7.4.5.2. Reagents
14.7.4.5.3. Assays
14.7.4.5.4. Probes
14.7.4.5.5. Others
14.7.5. Italy
14.7.5.1. Italy
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
14.7.5.1.1. Human
immunodeficiency virus (HIV)
14.7.5.1.2. Chlamydia
14.7.5.1.3. Trichomoniasis
14.7.5.1.4. Syphilis
14.7.5.1.5. Genital
Herpes
14.7.5.1.6. Epididymitis
14.7.5.1.7. Gonorrhoea
14.7.5.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.5.1.9. Vaginitis
14.7.5.1.9.1. Atrophic
vaginitis
14.7.5.1.9.2. Vulvodynia
14.7.5.1.10. Others
14.7.5.2. Italy
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
14.7.5.2.1. Microscopy
14.7.5.2.2. Point-of-care
(POC) antigen detection tests
14.7.5.2.3. Culture
14.7.5.2.4. Nucleic
acid amplification tests (NAATs)
14.7.5.2.5. Others
14.7.5.3. Italy
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.5.3.1. Swab
Tests
14.7.5.3.2. Urine
Tests
14.7.5.3.3. Blood
Tests
14.7.5.3.4. Combinational
Tests
14.7.5.4. Italy
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.5.4.1. Hospitals
14.7.5.4.2. Clinics
14.7.5.4.3. Laboratories
14.7.5.4.4. Pathological
Centres
14.7.5.4.5. Research
Institutes
14.7.5.4.6. Others
14.7.5.5. Italy
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
14.7.5.5.1. Test
Kits
14.7.5.5.2. Reagents
14.7.5.5.3. Assays
14.7.5.5.4. Probes
14.7.5.5.5. Others
14.7.6. Nordic
Countries
14.7.6.1. Nordic
Countries STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
14.7.6.1.1. Human
immunodeficiency virus (HIV)
14.7.6.1.2. Chlamydia
14.7.6.1.3. Trichomoniasis
14.7.6.1.4. Syphilis
14.7.6.1.5. Genital
Herpes
14.7.6.1.6. Epididymitis
14.7.6.1.7. Gonorrhoea
14.7.6.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.6.1.9. Vaginitis
14.7.6.1.9.1. Atrophic
vaginitis
14.7.6.1.9.2. Vulvodynia
14.7.6.1.10. Others
14.7.6.2. Nordic
Countries STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technologies
14.7.6.2.1. Microscopy
14.7.6.2.2. Point-of-care
(POC) antigen detection tests
14.7.6.2.3. Culture
14.7.6.2.4. Nucleic
acid amplification tests (NAATs)
14.7.6.2.5. Others
14.7.6.3. Nordic
Countries STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.6.3.1. Swab
Tests
14.7.6.3.2. Urine
Tests
14.7.6.3.3. Blood
Tests
14.7.6.3.4. Combinational
Tests
14.7.6.4. Nordic
Countries STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.6.4.1. Hospitals
14.7.6.4.2. Clinics
14.7.6.4.3. Laboratories
14.7.6.4.4. Pathological
Centres
14.7.6.4.5. Research
Institutes
14.7.6.4.6. Others
14.7.6.5. Nordic
Countries STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
14.7.6.5.1. Test
Kits
14.7.6.5.2. Reagents
14.7.6.5.3. Assays
14.7.6.5.4. Probes
14.7.6.5.5. Others
14.7.6.6. Nordic
Countries STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux
Union STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
14.7.7.1.1. Human
immunodeficiency virus (HIV)
14.7.7.1.2. Chlamydia
14.7.7.1.3. Trichomoniasis
14.7.7.1.4. Syphilis
14.7.7.1.5. Genital
Herpes
14.7.7.1.6. Epididymitis
14.7.7.1.7. Gonorrhoea
14.7.7.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.7.1.9. Vaginitis
14.7.7.1.9.1. Atrophic
vaginitis
14.7.7.1.9.2. Vulvodynia
14.7.7.1.10. Others
14.7.7.2. Benelux
Union STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
14.7.7.2.1. Microscopy
14.7.7.2.2. Point-of-care
(POC) antigen detection tests
14.7.7.2.3. Culture
14.7.7.2.4. Nucleic
acid amplification tests (NAATs)
14.7.7.2.5. Others
14.7.7.3. Benelux
Union STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.7.3.1. Swab
Tests
14.7.7.3.2. Urine
Tests
14.7.7.3.3. Blood
Tests
14.7.7.3.4. Combinational
Tests
14.7.7.4. Benelux
Union STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.7.4.1. Hospitals
14.7.7.4.2. Clinics
14.7.7.4.3. Laboratories
14.7.7.4.4. Pathological
Centres
14.7.7.4.5. Research
Institutes
14.7.7.4.6. Others
14.7.7.5. Benelux
Union STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
14.7.7.5.1. Test
Kits
14.7.7.5.2. Reagents
14.7.7.5.3. Assays
14.7.7.5.4. Probes
14.7.7.5.5. Others
14.7.7.6. Benelux
Union STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest
of Europe STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
14.7.8.1.1. Human
immunodeficiency virus (HIV)
14.7.8.1.2. Chlamydia
14.7.8.1.3. Trichomoniasis
14.7.8.1.4. Syphilis
14.7.8.1.5. Genital
Herpes
14.7.8.1.6. Epididymitis
14.7.8.1.7. Gonorrhoea
14.7.8.1.8. Genital
Warts/Human Papillomavirus (HPV)
14.7.8.1.9. Vaginitis
14.7.8.1.9.1. Atrophic
vaginitis
14.7.8.1.9.2. Vulvodynia
14.7.8.1.10. Others
14.7.8.2. Rest
of Europe STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technologies
14.7.8.2.1. Microscopy
14.7.8.2.2. Point-of-care
(POC) antigen detection tests
14.7.8.2.3. Culture
14.7.8.2.4. Nucleic
acid amplification tests (NAATs)
14.7.8.2.5. Others
14.7.8.3. Rest
of Europe STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
14.7.8.3.1. Swab
Tests
14.7.8.3.2. Urine
Tests
14.7.8.3.3. Blood
Tests
14.7.8.3.4. Combinational
Tests
14.7.8.4. Rest
of Europe STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.8.4.1. Hospitals
14.7.8.4.2. Clinics
14.7.8.4.3. Laboratories
14.7.8.4.4. Pathological
Centres
14.7.8.4.5. Research
Institutes
14.7.8.4.6. Others
14.7.8.5. Rest
of Europe STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
14.7.8.5.1. Test
Kits
14.7.8.5.2. Reagents
14.7.8.5.3. Assays
14.7.8.5.4. Probes
14.7.8.5.5. Others
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By
Clinical Indications
14.8.3. By
Technologies
14.8.4. By Test
Types
14.8.5. By End User
14.8.6. By
Product Offerings
15. Asia
Pacific STD Diagnostics Market Analysis and Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Asia
Pacific STD Diagnostics Market Revenue (US$ Mn)
15.2. Asia
Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
15.2.1. Human
immunodeficiency virus (HIV)
15.2.2. Chlamydia
15.2.3. Trichomoniasis
15.2.4. Syphilis
15.2.5. Genital
Herpes
15.2.6. Epididymitis
15.2.7. Gonorrhoea
15.2.8. Genital
Warts/Human Papillomavirus (HPV)
15.2.9. Vaginitis
15.2.9.1. Atrophic
vaginitis
15.2.9.2. Vulvodynia
15.2.10. Others
15.3. Asia
Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.3.1. Microscopy
15.3.2. Point-of-care
(POC) antigen detection tests
15.3.3. Culture
15.3.4. Nucleic
acid amplification tests (NAATs)
15.3.5. Others
15.4. Asia
Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.4.1. Swab
Tests
15.4.2. Urine
Tests
15.4.3. Blood
Tests
15.4.4. Combinational
Tests
15.5. Asia
Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Laboratories
15.5.4. Pathological
Centres
15.5.5. Research
Institutes
15.5.6. Others
15.6. Asia
Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
15.6.1. Test
Kits
15.6.2. Reagents
15.6.3. Assays
15.6.4. Probes
15.6.5. Others
15.7. Asia
Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1. China
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
15.7.1.1.1. Human
immunodeficiency virus (HIV)
15.7.1.1.2. Chlamydia
15.7.1.1.3. Trichomoniasis
15.7.1.1.4. Syphilis
15.7.1.1.5. Genital
Herpes
15.7.1.1.6. Epididymitis
15.7.1.1.7. Gonorrhoea
15.7.1.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.1.1.9. Vaginitis
15.7.1.1.9.1. Atrophic
vaginitis
15.7.1.1.9.2. Vulvodynia
15.7.1.1.10. Others
15.7.1.2. China
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.7.1.2.1. Microscopy
15.7.1.2.2. Point-of-care
(POC) antigen detection tests
15.7.1.2.3. Culture
15.7.1.2.4. Nucleic
acid amplification tests (NAATs)
15.7.1.2.5. Others
15.7.1.3. China
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.7.1.3.1. Swab
Tests
15.7.1.3.2. Urine
Tests
15.7.1.3.3. Blood
Tests
15.7.1.3.4. Combinational
Tests
15.7.1.4. China
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.1.4.1. Hospitals
15.7.1.4.2. Clinics
15.7.1.4.3. Laboratories
15.7.1.4.4. Pathological
Centres
15.7.1.4.5. Research
Institutes
15.7.1.4.6. Others
15.7.1.5. China
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
15.7.1.5.1. Test
Kits
15.7.1.5.2. Reagents
15.7.1.5.3. Assays
15.7.1.5.4. Probes
15.7.1.5.5. Others
15.7.2. Japan
15.7.2.1. Japan
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
15.7.2.1.1. Human
immunodeficiency virus (HIV)
15.7.2.1.2. Chlamydia
15.7.2.1.3. Trichomoniasis
15.7.2.1.4. Syphilis
15.7.2.1.5. Genital
Herpes
15.7.2.1.6. Epididymitis
15.7.2.1.7. Gonorrhoea
15.7.2.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.2.1.9. Vaginitis
15.7.2.1.9.1. Atrophic
vaginitis
15.7.2.1.9.2. Vulvodynia
15.7.2.1.10. Others
15.7.2.2. Japan
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.7.2.2.1. Microscopy
15.7.2.2.2. Point-of-care
(POC) antigen detection tests
15.7.2.2.3. Culture
15.7.2.2.4. Nucleic
acid amplification tests (NAATs)
15.7.2.2.5. Others
15.7.2.3. Japan
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.7.2.3.1. Swab
Tests
15.7.2.3.2. Urine
Tests
15.7.2.3.3. Blood
Tests
15.7.2.3.4. Combinational
Tests
15.7.2.4. Japan
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.2.4.1. Hospitals
15.7.2.4.2. Clinics
15.7.2.4.3. Laboratories
15.7.2.4.4. Pathological
Centres
15.7.2.4.5. Research
Institutes
15.7.2.4.6. Others
15.7.2.5. Japan
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
15.7.2.5.1. Test
Kits
15.7.2.5.2. Reagents
15.7.2.5.3. Assays
15.7.2.5.4. Probes
15.7.2.5.5. Others
15.7.3. India
15.7.3.1. India
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
15.7.3.1.1. Human
immunodeficiency virus (HIV)
15.7.3.1.2. Chlamydia
15.7.3.1.3. Trichomoniasis
15.7.3.1.4. Syphilis
15.7.3.1.5. Genital
Herpes
15.7.3.1.6. Epididymitis
15.7.3.1.7. Gonorrhoea
15.7.3.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.3.1.9. Vaginitis
15.7.3.1.9.1. Atrophic
vaginitis
15.7.3.1.9.2. Vulvodynia
15.7.3.1.10. Others
15.7.3.2. India
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.7.3.2.1. Microscopy
15.7.3.2.2. Point-of-care
(POC) antigen detection tests
15.7.3.2.3. Culture
15.7.3.2.4. Nucleic
acid amplification tests (NAATs)
15.7.3.2.5. Others
15.7.3.3. India
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.7.3.3.1. Swab
Tests
15.7.3.3.2. Urine
Tests
15.7.3.3.3. Blood
Tests
15.7.3.3.4. Combinational
Tests
15.7.3.4. India
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.3.4.1. Hospitals
15.7.3.4.2. Clinics
15.7.3.4.3. Laboratories
15.7.3.4.4. Pathological
Centres
15.7.3.4.5. Research
Institutes
15.7.3.4.6. Others
15.7.3.5. India
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
15.7.3.5.1. Test
Kits
15.7.3.5.2. Reagents
15.7.3.5.3. Assays
15.7.3.5.4. Probes
15.7.3.5.5. Others
15.7.4. New
Zealand
15.7.4.1. New
Zealand STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
15.7.4.1.1. Human
immunodeficiency virus (HIV)
15.7.4.1.2. Chlamydia
15.7.4.1.3. Trichomoniasis
15.7.4.1.4. Syphilis
15.7.4.1.5. Genital
Herpes
15.7.4.1.6. Epididymitis
15.7.4.1.7. Gonorrhoea
15.7.4.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.4.1.9. Vaginitis
15.7.4.1.9.1. Atrophic
vaginitis
15.7.4.1.9.2. Vulvodynia
15.7.4.1.10. Others
15.7.4.2. New
Zealand STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.7.4.2.1. Microscopy
15.7.4.2.2. Point-of-care
(POC) antigen detection tests
15.7.4.2.3. Culture
15.7.4.2.4. Nucleic
acid amplification tests (NAATs)
15.7.4.2.5. Others
15.7.4.3. New
Zealand STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.7.4.3.1. Swab
Tests
15.7.4.3.2. Urine
Tests
15.7.4.3.3. Blood
Tests
15.7.4.3.4. Combinational
Tests
15.7.4.4. New
Zealand STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.4.4.1. Hospitals
15.7.4.4.2. Clinics
15.7.4.4.3. Laboratories
15.7.4.4.4. Pathological
Centres
15.7.4.4.5. Research
Institutes
15.7.4.4.6. Others
15.7.4.5. New Zealand
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
15.7.4.5.1. Test
Kits
15.7.4.5.2. Reagents
15.7.4.5.3. Assays
15.7.4.5.4. Probes
15.7.4.5.5. Others
15.7.5. Australia
15.7.5.1. Australia
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
15.7.5.1.1. Human
immunodeficiency virus (HIV)
15.7.5.1.2. Chlamydia
15.7.5.1.3. Trichomoniasis
15.7.5.1.4. Syphilis
15.7.5.1.5. Genital
Herpes
15.7.5.1.6. Epididymitis
15.7.5.1.7. Gonorrhoea
15.7.5.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.5.1.9. Vaginitis
15.7.5.1.9.1. Atrophic
vaginitis
15.7.5.1.9.2. Vulvodynia
15.7.5.1.10. Others
15.7.5.2. Australia
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.7.5.2.1. Microscopy
15.7.5.2.2. Point-of-care
(POC) antigen detection tests
15.7.5.2.3. Culture
15.7.5.2.4. Nucleic
acid amplification tests (NAATs)
15.7.5.2.5. Others
15.7.5.3. Australia
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.7.5.3.1. Swab
Tests
15.7.5.3.2. Urine
Tests
15.7.5.3.3. Blood
Tests
15.7.5.3.4. Combinational
Tests
15.7.5.4. Australia
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.5.4.1. Hospitals
15.7.5.4.2. Clinics
15.7.5.4.3. Laboratories
15.7.5.4.4. Pathological
Centres
15.7.5.4.5. Research
Institutes
15.7.5.4.6. Others
15.7.5.5. Australia
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
15.7.5.5.1. Test
Kits
15.7.5.5.2. Reagents
15.7.5.5.3. Assays
15.7.5.5.4. Probes
15.7.5.5.5. Others
15.7.6. South
Korea
15.7.6.1. South
Korea STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
15.7.6.1.1. Human
immunodeficiency virus (HIV)
15.7.6.1.2. Chlamydia
15.7.6.1.3. Trichomoniasis
15.7.6.1.4. Syphilis
15.7.6.1.5. Genital
Herpes
15.7.6.1.6. Epididymitis
15.7.6.1.7. Gonorrhoea
15.7.6.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.6.1.9. Vaginitis
15.7.6.1.9.1. Atrophic
vaginitis
15.7.6.1.9.2. Vulvodynia
15.7.6.1.10. Others
15.7.6.2. South
Korea STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.7.6.2.1. Microscopy
15.7.6.2.2. Point-of-care
(POC) antigen detection tests
15.7.6.2.3. Culture
15.7.6.2.4. Nucleic
acid amplification tests (NAATs)
15.7.6.2.5. Others
15.7.6.3. South
Korea STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.7.6.3.1. Swab
Tests
15.7.6.3.2. Urine
Tests
15.7.6.3.3. Blood
Tests
15.7.6.3.4. Combinational
Tests
15.7.6.4. South
Korea STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.6.4.1. Hospitals
15.7.6.4.2. Clinics
15.7.6.4.3. Laboratories
15.7.6.4.4. Pathological
Centres
15.7.6.4.5. Research
Institutes
15.7.6.4.6. Others
15.7.6.5. South
Korea STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
15.7.6.5.1. Test
Kits
15.7.6.5.2. Reagents
15.7.6.5.3. Assays
15.7.6.5.4. Probes
15.7.6.5.5. Others
15.7.7. Southeast
Asia
15.7.7.1. Southeast
Asia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
15.7.7.1.1. Human
immunodeficiency virus (HIV)
15.7.7.1.2. Chlamydia
15.7.7.1.3. Trichomoniasis
15.7.7.1.4. Syphilis
15.7.7.1.5. Genital
Herpes
15.7.7.1.6. Epididymitis
15.7.7.1.7. Gonorrhoea
15.7.7.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.7.1.9. Vaginitis
15.7.7.1.9.1. Atrophic
vaginitis
15.7.7.1.9.2. Vulvodynia
15.7.7.1.10. Others
15.7.7.2. Southeast
Asia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
15.7.7.2.1. Microscopy
15.7.7.2.2. Point-of-care
(POC) antigen detection tests
15.7.7.2.3. Culture
15.7.7.2.4. Nucleic
acid amplification tests (NAATs)
15.7.7.2.5. Others
15.7.7.3. Southeast
Asia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
15.7.7.3.1. Swab
Tests
15.7.7.3.2. Urine
Tests
15.7.7.3.3. Blood
Tests
15.7.7.3.4. Combinational
Tests
15.7.7.4. Southeast
Asia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.7.4.1. Hospitals
15.7.7.4.2. Clinics
15.7.7.4.3. Laboratories
15.7.7.4.4. Pathological
Centres
15.7.7.4.5. Research
Institutes
15.7.7.4.6. Others
15.7.7.5. Southeast
Asia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
15.7.7.5.1. Test
Kits
15.7.7.5.2. Reagents
15.7.7.5.3. Assays
15.7.7.5.4. Probes
15.7.7.5.5. Others
15.7.7.6. Southeast
Asia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest
of Asia Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Clinical Indications
15.7.8.1.1. Human
immunodeficiency virus (HIV)
15.7.8.1.2. Chlamydia
15.7.8.1.3. Trichomoniasis
15.7.8.1.4. Syphilis
15.7.8.1.5. Genital
Herpes
15.7.8.1.6. Epididymitis
15.7.8.1.7. Gonorrhoea
15.7.8.1.8. Genital
Warts/Human Papillomavirus (HPV)
15.7.8.1.9. Vaginitis
15.7.8.1.9.1. Atrophic
vaginitis
15.7.8.1.9.2. Vulvodynia
15.7.8.1.10. Others
15.7.8.2. Rest
of Asia Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technologies
15.7.8.2.1. Microscopy
15.7.8.2.2. Point-of-care
(POC) antigen detection tests
15.7.8.2.3. Culture
15.7.8.2.4. Nucleic
acid amplification tests (NAATs)
15.7.8.2.5. Others
15.7.8.3. Rest
of Asia Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test
Types
15.7.8.3.1. Swab
Tests
15.7.8.3.2. Urine
Tests
15.7.8.3.3. Blood
Tests
15.7.8.3.4. Combinational
Tests
15.7.8.4. Rest
of Asia Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End
User
15.7.8.4.1. Hospitals
15.7.8.4.2. Clinics
15.7.8.4.3. Laboratories
15.7.8.4.4. Pathological
Centres
15.7.8.4.5. Research
Institutes
15.7.8.4.6. Others
15.7.8.5. Rest
of Asia Pacific STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Product Offerings
15.7.8.5.1. Test
Kits
15.7.8.5.2. Reagents
15.7.8.5.3. Assays
15.7.8.5.4. Probes
15.7.8.5.5. Others
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By
Clinical Indications
15.8.3. By
Technologies
15.8.4. By Test
Types
15.8.5. By End
User
15.8.6. By
Product Offerings
16. Middle
East and Africa STD Diagnostics Market Analysis and Forecasts, 2019 - 2027
16.1. Overview
16.1.1. Middle
East and Africa STD Diagnostics Market Revenue (US$ Mn)
16.2. Middle
East and Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Clinical Indications
16.2.1. Human
immunodeficiency virus (HIV)
16.2.2. Chlamydia
16.2.3. Trichomoniasis
16.2.4. Syphilis
16.2.5. Genital
Herpes
16.2.6. Epididymitis
16.2.7. Gonorrhoea
16.2.8. Genital
Warts/Human Papillomavirus (HPV)
16.2.9. Vaginitis
16.2.9.1. Atrophic
vaginitis
16.2.9.2. Vulvodynia
16.2.10. Others
16.3. Middle
East and Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technologies
16.3.1. Microscopy
16.3.2. Point-of-care
(POC) antigen detection tests
16.3.3. Culture
16.3.4. Nucleic
acid amplification tests (NAATs)
16.3.5. Others
16.4. Middle
East and Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test
Types
16.4.1. Swab
Tests
16.4.2. Urine
Tests
16.4.3. Blood
Tests
16.4.4. Combinational
Tests
16.5. Middle
East and Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End
User
16.5.1. Hospitals
16.5.2. Clinics
16.5.3. Laboratories
16.5.4. Pathological
Centres
16.5.5. Research
Institutes
16.5.6. Others
16.6. Middle
East and Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Product Offerings
16.6.1. Test
Kits
16.6.2. Reagents
16.6.3. Assays
16.6.4. Probes
16.6.5. Others
16.7. Middle
East and Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi
Arabia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
16.7.1.1.1. Human
immunodeficiency virus (HIV)
16.7.1.1.2. Chlamydia
16.7.1.1.3. Trichomoniasis
16.7.1.1.4. Syphilis
16.7.1.1.5. Genital
Herpes
16.7.1.1.6. Epididymitis
16.7.1.1.7. Gonorrhoea
16.7.1.1.8. Genital
Warts/Human Papillomavirus (HPV)
16.7.1.1.9. Vaginitis
16.7.1.1.9.1. Atrophic
vaginitis
16.7.1.1.9.2. Vulvodynia
16.7.1.1.10. Others
16.7.1.2. Saudi
Arabia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
16.7.1.2.1. Microscopy
16.7.1.2.2. Point-of-care
(POC) antigen detection tests
16.7.1.2.3. Culture
16.7.1.2.4. Nucleic
acid amplification tests (NAATs)
16.7.1.2.5. Others
16.7.1.3. Saudi
Arabia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
16.7.1.3.1. Swab
Tests
16.7.1.3.2. Urine
Tests
16.7.1.3.3. Blood
Tests
16.7.1.3.4. Combinational
Tests
16.7.1.4. Saudi
Arabia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.1.4.1. Hospitals
16.7.1.4.2. Clinics
16.7.1.4.3. Laboratories
16.7.1.4.4. Pathological
Centres
16.7.1.4.5. Research
Institutes
16.7.1.4.6. Others
16.7.1.5. Saudi
Arabia STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
16.7.1.5.1. Test
Kits
16.7.1.5.2. Reagents
16.7.1.5.3. Assays
16.7.1.5.4. Probes
16.7.1.5.5. Others
16.7.2. UAE
16.7.2.1. UAE
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
16.7.2.1.1. Human
immunodeficiency virus (HIV)
16.7.2.1.2. Chlamydia
16.7.2.1.3. Trichomoniasis
16.7.2.1.4. Syphilis
16.7.2.1.5. Genital
Herpes
16.7.2.1.6. Epididymitis
16.7.2.1.7. Gonorrhoea
16.7.2.1.8. Genital
Warts/Human Papillomavirus (HPV)
16.7.2.1.9. Vaginitis
16.7.2.1.9.1. Atrophic
vaginitis
16.7.2.1.9.2. Vulvodynia
16.7.2.1.10. Others
16.7.2.2. UAE
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
16.7.2.2.1. Microscopy
16.7.2.2.2. Point-of-care
(POC) antigen detection tests
16.7.2.2.3. Culture
16.7.2.2.4. Nucleic
acid amplification tests (NAATs)
16.7.2.2.5. Others
16.7.2.3. UAE
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
16.7.2.3.1. Swab
Tests
16.7.2.3.2. Urine
Tests
16.7.2.3.3. Blood
Tests
16.7.2.3.4. Combinational
Tests
16.7.2.4. UAE
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.2.4.1. Hospitals
16.7.2.4.2. Clinics
16.7.2.4.3. Laboratories
16.7.2.4.4. Pathological
Centres
16.7.2.4.5. Research
Institutes
16.7.2.4.6. Others
16.7.2.5. UAE
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
16.7.2.5.1. Test
Kits
16.7.2.5.2. Reagents
16.7.2.5.3. Assays
16.7.2.5.4. Probes
16.7.2.5.5. Others
16.7.3. Egypt
16.7.3.1. Egypt
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
16.7.3.1.1. Human
immunodeficiency virus (HIV)
16.7.3.1.2. Chlamydia
16.7.3.1.3. Trichomoniasis
16.7.3.1.4. Syphilis
16.7.3.1.5. Genital
Herpes
16.7.3.1.6. Epididymitis
16.7.3.1.7. Gonorrhoea
16.7.3.1.8. Genital
Warts/Human Papillomavirus (HPV)
16.7.3.1.9. Vaginitis
16.7.3.1.9.1. Atrophic
vaginitis
16.7.3.1.9.2. Vulvodynia
16.7.3.1.10. Others
16.7.3.2. Egypt
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
16.7.3.2.1. Microscopy
16.7.3.2.2. Point-of-care
(POC) antigen detection tests
16.7.3.2.3. Culture
16.7.3.2.4. Nucleic
acid amplification tests (NAATs)
16.7.3.2.5. Others
16.7.3.3. Egypt
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
16.7.3.3.1. Swab
Tests
16.7.3.3.2. Urine
Tests
16.7.3.3.3. Blood
Tests
16.7.3.3.4. Combinational
Tests
16.7.3.4. Egypt
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.3.4.1. Hospitals
16.7.3.4.2. Clinics
16.7.3.4.3. Laboratories
16.7.3.4.4. Pathological
Centres
16.7.3.4.5. Research
Institutes
16.7.3.4.6. Others
16.7.3.5. Egypt
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
16.7.3.5.1. Test
Kits
16.7.3.5.2. Reagents
16.7.3.5.3. Assays
16.7.3.5.4. Probes
16.7.3.5.5. Others
16.7.4. Kuwait
16.7.4.1. Kuwait
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
16.7.4.1.1. Human
immunodeficiency virus (HIV)
16.7.4.1.2. Chlamydia
16.7.4.1.3. Trichomoniasis
16.7.4.1.4. Syphilis
16.7.4.1.5. Genital
Herpes
16.7.4.1.6. Epididymitis
16.7.4.1.7. Gonorrhoea
16.7.4.1.8. Genital
Warts/Human Papillomavirus (HPV)
16.7.4.1.9. Vaginitis
16.7.4.1.9.1. Atrophic
vaginitis
16.7.4.1.9.2. Vulvodynia
16.7.4.1.10. Others
16.7.4.2. Kuwait
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
16.7.4.2.1. Microscopy
16.7.4.2.2. Point-of-care
(POC) antigen detection tests
16.7.4.2.3. Culture
16.7.4.2.4. Nucleic
acid amplification tests (NAATs)
16.7.4.2.5. Others
16.7.4.3. Kuwait
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
16.7.4.3.1. Swab
Tests
16.7.4.3.2. Urine
Tests
16.7.4.3.3. Blood
Tests
16.7.4.3.4. Combinational
Tests
16.7.4.4. Kuwait
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.4.4.1. Hospitals
16.7.4.4.2. Clinics
16.7.4.4.3. Laboratories
16.7.4.4.4. Pathological
Centres
16.7.4.4.5. Research
Institutes
16.7.4.4.6. Others
16.7.4.5. Kuwait
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
16.7.4.5.1. Test
Kits
16.7.4.5.2. Reagents
16.7.4.5.3. Assays
16.7.4.5.4. Probes
16.7.4.5.5. Others
16.7.5. South
Africa
16.7.5.1. South
Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
16.7.5.1.1. Human
immunodeficiency virus (HIV)
16.7.5.1.2. Chlamydia
16.7.5.1.3. Trichomoniasis
16.7.5.1.4. Syphilis
16.7.5.1.5. Genital
Herpes
16.7.5.1.6. Epididymitis
16.7.5.1.7. Gonorrhoea
16.7.5.1.8. Genital
Warts/Human Papillomavirus (HPV)
16.7.5.1.9. Vaginitis
16.7.5.1.9.1. Atrophic
vaginitis
16.7.5.1.9.2. Vulvodynia
16.7.5.1.10. Others
16.7.5.2. South
Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
16.7.5.2.1. Microscopy
16.7.5.2.2. Point-of-care
(POC) antigen detection tests
16.7.5.2.3. Culture
16.7.5.2.4. Nucleic
acid amplification tests (NAATs)
16.7.5.2.5. Others
16.7.5.3. South
Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
16.7.5.3.1. Swab
Tests
16.7.5.3.2. Urine
Tests
16.7.5.3.3. Blood
Tests
16.7.5.3.4. Combinational
Tests
16.7.5.4. South
Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.5.4.1. Hospitals
16.7.5.4.2. Clinics
16.7.5.4.3. Laboratories
16.7.5.4.4. Pathological
Centres
16.7.5.4.5. Research
Institutes
16.7.5.4.6. Others
16.7.5.5. South
Africa STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
16.7.5.5.1. Test
Kits
16.7.5.5.2. Reagents
16.7.5.5.3. Assays
16.7.5.5.4. Probes
16.7.5.5.5. Others
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest
of Middle East & Africa STD Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Clinical Indications
16.7.6.1.1. Human
immunodeficiency virus (HIV)
16.7.6.1.2. Chlamydia
16.7.6.1.3. Trichomoniasis
16.7.6.1.4. Syphilis
16.7.6.1.5. Genital
Herpes
16.7.6.1.6. Epididymitis
16.7.6.1.7. Gonorrhoea
16.7.6.1.8. Genital
Warts/Human Papillomavirus (HPV)
16.7.6.1.9. Vaginitis
16.7.6.1.9.1. Atrophic
vaginitis
16.7.6.1.9.2. Vulvodynia
16.7.6.1.10. Others
16.7.6.2. Rest
of Middle East & Africa STD Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Technologies
16.7.6.2.1. Microscopy
16.7.6.2.2. Point-of-care
(POC) antigen detection tests
16.7.6.2.3. Culture
16.7.6.2.4. Nucleic
acid amplification tests (NAATs)
16.7.6.2.5. Others
16.7.6.3. Rest
of Middle East & Africa STD Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Test Types
16.7.6.3.1. Swab
Tests
16.7.6.3.2. Urine
Tests
16.7.6.3.3. Blood
Tests
16.7.6.3.4. Combinational
Tests
16.7.6.4. Rest
of Middle East & Africa STD Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
16.7.6.4.1. Hospitals
16.7.6.4.2. Clinics
16.7.6.4.3. Laboratories
16.7.6.4.4. Pathological
Centres
16.7.6.4.5. Research
Institutes
16.7.6.4.6. Others
16.7.6.5. Rest
of Middle East & Africa STD Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Product Offerings
16.7.6.5.1. Test
Kits
16.7.6.5.2. Reagents
16.7.6.5.3. Assays
16.7.6.5.4. Probes
16.7.6.5.5. Others
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By
Clinical Indications
16.8.3. By
Technologies
16.8.4. By Test
Types
16.8.5. By End
User
16.8.6. By
Product Offerings
17. Latin
America STD Diagnostics Market Analysis and Forecasts, 2019 - 2027
17.1. Overview
17.1.1. Latin
America STD Diagnostics Market Revenue (US$ Mn)
17.2. Latin
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical
Indications
17.2.1. Human immunodeficiency
virus (HIV)
17.2.2. Chlamydia
17.2.3. Trichomoniasis
17.2.4. Syphilis
17.2.5. Genital
Herpes
17.2.6. Epididymitis
17.2.7. Gonorrhoea
17.2.8. Genital
Warts/Human Papillomavirus (HPV)
17.2.9. Vaginitis
17.2.9.1. Atrophic
vaginitis
17.2.9.2. Vulvodynia
17.2.10. Others
17.3. Latin
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
17.3.1. Microscopy
17.3.2. Point-of-care
(POC) antigen detection tests
17.3.3. Culture
17.3.4. Nucleic
acid amplification tests (NAATs)
17.3.5. Others
17.4. Latin
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
17.4.1. Swab
Tests
17.4.2. Urine
Tests
17.4.3. Blood
Tests
17.4.4. Combinational
Tests
17.5. Latin
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
17.5.1. Hospitals
17.5.2. Clinics
17.5.3. Laboratories
17.5.4. Pathological
Centres
17.5.5. Research
Institutes
17.5.6. Others
17.6. Latin
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product
Offerings
17.6.1. Test
Kits
17.6.2. Reagents
17.6.3. Assays
17.6.4. Probes
17.6.5. Others
17.7. Latin
America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
17.7.1.1.1. Human
immunodeficiency virus (HIV)
17.7.1.1.2. Chlamydia
17.7.1.1.3. Trichomoniasis
17.7.1.1.4. Syphilis
17.7.1.1.5. Genital
Herpes
17.7.1.1.6. Epididymitis
17.7.1.1.7. Gonorrhoea
17.7.1.1.8. Genital
Warts/Human Papillomavirus (HPV)
17.7.1.1.9. Vaginitis
17.7.1.1.9.1. Atrophic
vaginitis
17.7.1.1.9.2. Vulvodynia
17.7.1.1.10. Others
17.7.1.2. Brazil
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
17.7.1.2.1. Microscopy
17.7.1.2.2. Point-of-care
(POC) antigen detection tests
17.7.1.2.3. Culture
17.7.1.2.4. Nucleic
acid amplification tests (NAATs)
17.7.1.2.5. Others
17.7.1.3. Brazil
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
17.7.1.3.1. Swab
Tests
17.7.1.3.2. Urine
Tests
17.7.1.3.3. Blood
Tests
17.7.1.3.4. Combinational
Tests
17.7.1.4. Brazil
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
17.7.1.4.1. Hospitals
17.7.1.4.2. Clinics
17.7.1.4.3. Laboratories
17.7.1.4.4. Pathological
Centres
17.7.1.4.5. Research
Institutes
17.7.1.4.6. Others
17.7.1.5. Brazil
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
17.7.1.5.1. Test
Kits
17.7.1.5.2. Reagents
17.7.1.5.3. Assays
17.7.1.5.4. Probes
17.7.1.5.5. Others
17.7.2. Argentina
17.7.2.1. Argentina
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Clinical Indications
17.7.2.1.1. Human
immunodeficiency virus (HIV)
17.7.2.1.2. Chlamydia
17.7.2.1.3. Trichomoniasis
17.7.2.1.4. Syphilis
17.7.2.1.5. Genital
Herpes
17.7.2.1.6. Epididymitis
17.7.2.1.7. Gonorrhoea
17.7.2.1.8. Genital
Warts/Human Papillomavirus (HPV)
17.7.2.1.9. Vaginitis
17.7.2.1.9.1. Atrophic
vaginitis
17.7.2.1.9.2. Vulvodynia
17.7.2.1.10. Others
17.7.2.2. Argentina
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technologies
17.7.2.2.1. Microscopy
17.7.2.2.2. Point-of-care
(POC) antigen detection tests
17.7.2.2.3. Culture
17.7.2.2.4. Nucleic
acid amplification tests (NAATs)
17.7.2.2.5. Others
17.7.2.3. Argentina
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test Types
17.7.2.3.1. Swab
Tests
17.7.2.3.2. Urine
Tests
17.7.2.3.3. Blood
Tests
17.7.2.3.4. Combinational
Tests
17.7.2.4. Argentina
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
17.7.2.4.1. Hospitals
17.7.2.4.2. Clinics
17.7.2.4.3. Laboratories
17.7.2.4.4. Pathological
Centres
17.7.2.4.5. Research
Institutes
17.7.2.4.6. Others
17.7.2.5. Argentina
STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Product Offerings
17.7.2.5.1. Test
Kits
17.7.2.5.2. Reagents
17.7.2.5.3. Assays
17.7.2.5.4. Probes
17.7.2.5.5. Others
17.7.3. Rest of
Latin America
17.7.3.1. Rest
of Latin America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Clinical Indications
17.7.3.1.1. Human
immunodeficiency virus (HIV)
17.7.3.1.2. Chlamydia
17.7.3.1.3. Trichomoniasis
17.7.3.1.4. Syphilis
17.7.3.1.5. Genital
Herpes
17.7.3.1.6. Epididymitis
17.7.3.1.7. Gonorrhoea
17.7.3.1.8. Genital
Warts/Human Papillomavirus (HPV)
17.7.3.1.9. Vaginitis
17.7.3.1.9.1. Atrophic
vaginitis
17.7.3.1.9.2. Vulvodynia
17.7.3.1.10. Others
17.7.3.2. Rest
of Latin America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technologies
17.7.3.2.1. Microscopy
17.7.3.2.2. Point-of-care
(POC) antigen detection tests
17.7.3.2.3. Culture
17.7.3.2.4. Nucleic
acid amplification tests (NAATs)
17.7.3.2.5. Others
17.7.3.3. Rest
of Latin America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By Test
Types
17.7.3.3.1. Swab
Tests
17.7.3.3.2. Urine
Tests
17.7.3.3.3. Blood
Tests
17.7.3.3.4. Combinational
Tests
17.7.3.4. Rest
of Latin America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By End
User
17.7.3.4.1. Hospitals
17.7.3.4.2. Clinics
17.7.3.4.3. Laboratories
17.7.3.4.4. Pathological
Centres
17.7.3.4.5. Research
Institutes
17.7.3.4.6. Others
17.7.3.5. Rest
of Latin America STD Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Product Offerings
17.7.3.5.1. Test
Kits
17.7.3.5.2. Reagents
17.7.3.5.3. Assays
17.7.3.5.4. Probes
17.7.3.5.5. Others
17.8. Key
Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By
Clinical Indications
17.8.3. By
Technologies
17.8.4. By Test
Types
17.8.5. By End
User
17.8.6. By
Product Offerings
18. Competitive
Benchmarking
18.1. Market
Share Analysis, 2018
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player
Profiles
19.1. Abbott
Laboratories
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. BD
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business
Strategies
19.3. bioMérieux SA
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. Bio-Rad
Laboratories, Inc.
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. Cellabs
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Cepheid
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. Danaher Corporation
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business
Strategies
19.8. DiaSorin
S.p.A.
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. EUROSPITAL SPA
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT
Analysis
19.9.7. Business
Strategies
19.10. F.
Hoffmann-La Roche Ltd
19.10.1. Company
Details
19.10.2. Company
Overview
19.10.3. Product
Offerings
19.10.4. Key
Developments
19.10.5. Financial
Analysis
19.10.6. SWOT
Analysis
19.10.7. Business
Strategies
19.11. Hologic,
Inc.
19.11.1. Company
Details
19.11.2. Company
Overview
19.11.3. Product
Offerings
19.11.4. Key
Developments
19.11.5. Financial
Analysis
19.11.6. SWOT
Analysis
19.11.7. Business
Strategies
19.12. JAL Medical (OK Biotech Co. Ltd.)
19.12.1. Company
Details
19.12.2. Company
Overview
19.12.3. Product
Offerings
19.12.4. Key
Developments
19.12.5. Financial
Analysis
19.12.6. SWOT
Analysis
19.12.7. Business
Strategies
19.13. MedMira
Inc.
19.13.1. Company
Details
19.13.2. Company
Overview
19.13.3. Product
Offerings
19.13.4. Key
Developments
19.13.5. Financial
Analysis
19.13.6. SWOT
Analysis
19.13.7. Business
Strategies
19.14. OraSure
Technologies, Inc.
19.14.1. Company
Details
19.14.2. Company
Overview
19.14.3. Product
Offerings
19.14.4. Key
Developments
19.14.5. Financial
Analysis
19.14.6. SWOT
Analysis
19.14.7. Business
Strategies
19.15. QIAGEN
19.15.1. Company
Details
19.15.2. Company
Overview
19.15.3. Product
Offerings
19.15.4. Key
Developments
19.15.5. Financial
Analysis
19.15.6. SWOT
Analysis
19.15.7. Business
Strategies
19.16. Quest Diagnostics
19.16.1. Company
Details
19.16.2. Company
Overview
19.16.3. Product
Offerings
19.16.4. Key
Developments
19.16.5. Financial
Analysis
19.16.6. SWOT
Analysis
19.16.7. Business
Strategies
19.17. Quidel
Corporation
19.17.1. Company
Details
19.17.2. Company
Overview
19.17.3. Product
Offerings
19.17.4. Key
Developments
19.17.5. Financial
Analysis
19.17.6. SWOT
Analysis
19.17.7. Business
Strategies
19.18. Rapikit.com
19.18.1. Company
Details
19.18.2. Company
Overview
19.18.3. Product
Offerings
19.18.4. Key
Developments
19.18.5. Financial
Analysis
19.18.6. SWOT
Analysis
19.18.7. Business
Strategies
19.19. Siemens
Healthcare GmbH
19.19.1. Company
Details
19.19.2. Company
Overview
19.19.3. Product
Offerings
19.19.4. Key
Developments
19.19.5. Financial
Analysis
19.19.6. SWOT
Analysis
19.19.7. Business
Strategies
19.20. Other
Industry Participants
20. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.